14 November 2020 in Cardiovascular Therapy and Prevention
Резолюция экспертного совета “Актуальные вопросы железодефицита в Российской Федерации”
13 October 2020 in Meditsinskiy sovet = Medical Council
Методы лечения генитоуринарного синдрома на современном этапе
22 February 2016 in Almanac of Clinical Medicine
В репродуктивном возрасте распространенность сердечно-сосудистой патологии у женщин невелика. Но в этот период происходит формирование факторов риска развития сердечно-сосудистых заболеваний. К ним относят ожирение, артериальную гипертонию, дислипидемию, инсулинорезистентность, сахарный диабет и др. В обзоре показана связь факторов риска сердечно-сосудистых заболеваний с акушерской и гинекологической патологией начиная с менархе и заканчивая постменопаузой. Одним из показателей возрастных изменений сердечно-сосудистой системы принято считать степень выраженности старения сосудов. Выявлено наличие ассоциации между маркерами старения – длиной теломер и активностью теломеразы – и дефицитом эстрогенов.
15 February 2021 in GYNECOLOGY
The article presents the results of recent studies on the effectiveness, safety and duration of menopausal hormone therapy (MHT). The main cardio-metabolic risk factors for cardiovascular diseases are formed in women precisely during the transition to menopause and are clearly associated with the appearance of vegetative menopausal symptoms and the development of endothelial dysfunction, which is a predictor of future serious health problems, especially cardiovascular diseases. The results of a number of epidemiological studies have shown that in women with severe climacteric manifestations, especially with hot flashes, the overall risk of developing cardiovascular diseases is increased. The need for early initiation of MHT is an indisputable truth and is not disputed by anyone, but the formed tendency to discontinue treatment in 56 years raises many questions among patients and their doctors. However, recent guidelines from the International Menopause Society state that there is no reason to arbitrarily limit the duration of MHT. This paper presents current evidence on the indications and benefits of low and ultra-low doses of MHT. In view of the high efficacy and safety of low doses of MHT, they seem to be the most acceptable starting doses of oral MHT for most women. In addition, women with early menopause should also receive higher doses of estrogens, as they are more physiological for them. The choice in favor of starting MHT in a postmenopausal woman with a low or ultra-low dose in each case should be selected individually.
5 April 2019 in Meditsinskiy sovet = Medical Council
Clinical manifestations of hyperandrogenism can be an important diagnostic symptom of polycystic ovary syndrome, and in most cases allow establishing this diagnosis in a timely manner. The article discusses the problem of acne not only in adolescence, but also in adult women, and the problem of hirsutism in detail. It shows the role of combined oral contraceptives (COCs) as an effective therapy for acne and hirsutism in women, as well as the first-line therapy for polycystic ovary syndrome, according to the international and national clinical guidelines. The data summarize the effectiveness of the use of COCs containing drospirenone as a gestagenic component and levomefolate calcium in order to compensate for folate deficiency and, accordingly, reduce the level of homocysteine, which is often elevated in women with hyperandrogenism.
25 June 2020 in Akusherstvo i ginekologiia
DDDobrokhotova Yu.E. Dobrokhotova
Dobrokhotova Yu.E. Dobrokhotova
M(Moscow Zao “Nasledniki” (Heirs)
Moscow Zao “Nasledniki” (Heirs)
+5